KRAS and hepatitis A virus infection: A recent pharmacovigilance study found that when targeted therapies are combined with checkpoint inhibitors, KRAS‐directed agents were most strongly associated with the development of hepatitis, with a significant reporting odds ratio of 3.03 [7].